Published in Clin Infect Dis on February 14, 2013
Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis (2013) 3.00
School-located influenza vaccination decreases laboratory-confirmed influenza and improves school attendance. Clin Infect Dis (2014) 1.70
Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis (2014) 1.62
Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol (2013) 1.49
Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis (2014) 1.44
Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines (2014) 1.25
Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. J Infect Dis (2014) 1.23
Frequency of acute respiratory illnesses and circulation of respiratory viruses in households with children over 3 surveillance seasons. J Infect Dis (2014) 1.14
Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. J Infect Dis (2015) 1.08
Influenza transmission in a cohort of households with children: 2010-2011. PLoS One (2013) 1.07
Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One (2013) 1.06
Influenza vaccines: challenges and solutions. Cell Host Microbe (2015) 1.05
A Perfect Storm: Impact of Genomic Variation and Serial Vaccination on Low Influenza Vaccine Effectiveness During the 2014-2015 Season. Clin Infect Dis (2016) 1.02
Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. Am J Epidemiol (2016) 0.99
To dream the impossible dream: universal influenza vaccination. Curr Opin Virol (2013) 0.98
Factors associated with influenza vaccine receipt in community dwelling adults and their children. Vaccine (2014) 0.97
Factors influencing infection by pandemic influenza A(H1N1)pdm09 over three epidemic waves in Singapore. Influenza Other Respir Viruses (2013) 0.93
Effectiveness and knowledge, attitudes and practices of seasonal influenza vaccine in primary healthcare settings in South Africa, 2010-2013. Influenza Other Respir Viruses (2015) 0.93
Influenza vaccination coverage and effectiveness in young children in Thailand, 2011-2013. Influenza Other Respir Viruses (2015) 0.91
Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol (2015) 0.90
Mid-Season Estimates of Influenza Vaccine Effectiveness against Influenza A(H3N2) Hospitalization in the Elderly in Quebec, Canada, January 2015. PLoS One (2015) 0.89
First-year results of the Global Influenza Hospital Surveillance Network: 2012-2013 Northern hemisphere influenza season. BMC Public Health (2014) 0.88
The effect of age and recent influenza vaccination history on the immunogenicity and efficacy of 2009-10 seasonal trivalent inactivated influenza vaccination in children. PLoS One (2013) 0.88
Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults. Infect Chemother (2013) 0.87
Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination. J Infect Dis (2015) 0.86
Understanding suboptimal influenza vaccine effectiveness within the agent, host, and environment paradigm. Clin Infect Dis (2013) 0.86
Guidance for practitioners on the use of antiviral drugs to control influenza outbreaks in long-term care facilities in Canada, 2014-2015 season. Can J Infect Dis Med Microbiol (2015) 0.81
Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013-2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated. J Infect Dis (2015) 0.81
Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. J Infect Dis (2015) 0.80
Effect of gargling with tea and ingredients of tea on the prevention of influenza infection: a meta-analysis. BMC Public Health (2016) 0.79
How can we solve the enigma of influenza vaccine-induced protection? J Infect Dis (2014) 0.79
Influenza Vaccination of Healthcare Workers: Critical Analysis of the Evidence for Patient Benefit Underpinning Policies of Enforcement. PLoS One (2017) 0.79
Seroprotective antibodies to 2011 variant influenza A(H3N2v) and seasonal influenza A(H3N2) among three age groups of US Department of Defense service members. PLoS One (2015) 0.75
Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and post-hoc correlate of protection analysis. Hum Vaccin Immunother (2016) 0.75
Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults. Clin Infect Dis (2016) 0.75
Reply to Sullivan and Kelly and Skowronski et al. Clin Infect Dis (2013) 0.75
Editorial commentary: influenza vaccine: glass half full or half empty? Clin Infect Dis (2013) 0.75
Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013: The Importance of Two Priming Doses. Pediatr Infect Dis J (2016) 0.75
Geographical heterogeneity and influenza infection within households. BMC Infect Dis (2014) 0.75
Influenza Vaccine Effectiveness in a Low-Income, Urban Community Cohort. Clin Infect Dis (2015) 0.75
A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children. Hum Vaccin Immunother (2016) 0.75
Different Repeat Annual Influenza Vaccinations Improve the Antibody Response to Drifted Influenza Strains. Sci Rep (2017) 0.75
Synthetic TLR4 and TLR7 ligands work additively via MyD88 to induce protective antiviral immunity in mice. J Virol (2017) 0.75
Strategies for mitigating an influenza pandemic. Nature (2006) 25.20
Containing pandemic influenza at the source. Science (2005) 23.95
Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci U S A (2006) 17.88
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med (2010) 5.90
Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med (2006) 4.50
Variable efficacy of repeated annual influenza vaccination. Proc Natl Acad Sci U S A (1999) 3.35
Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis (2012) 2.91
Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One (2008) 2.83
Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ (2011) 2.50
Household transmission of the 2009 pandemic A/H1N1 influenza virus: elevated laboratory‐confirmed secondary attack rates and evidence of asymptomatic infections. Clin Infect Dis (2010) 2.41
Studies of the community and family: acute respiratory illness and infection. Epidemiol Rev (1994) 2.16
Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med (1999) 2.01
Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period. Vaccine (1997) 1.95
Transmissibility of seasonal and pandemic influenza in a cohort of households in Hong Kong in 2009. Epidemiology (2011) 1.95
Protective efficacy against pandemic influenza of seasonal influenza vaccination in children in Hong Kong: a randomized controlled trial. Clin Infect Dis (2012) 1.94
Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One (2011) 1.94
I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One (2011) 1.73
Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine (1996) 1.55
Immunogenicity, boostability, and sustainability of the immune response after vaccination against Influenza A virus (H1N1) 2009 in a healthy population. Clin Vaccine Immunol (2011) 1.33
Magnitude of potential biases in a simulated case-control study of the effectiveness of influenza vaccination. Clin Infect Dis (2011) 1.20
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
Influenza-associated hospitalizations in the United States. JAMA (2004) 18.23
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep (2008) 9.02
Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA (2006) 8.06
Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis (2012) 8.02
Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med (2005) 6.83
Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA (2005) 5.84
Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep (2009) 5.80
Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med (2003) 5.60
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep (2007) 5.32
Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (2006) 5.19
Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis (2004) 4.82
Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med (2007) 4.69
Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med (2006) 4.50
The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med (2003) 4.37
Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med (2007) 4.16
Human infection with avian influenza A H7N9 virus: an assessment of clinical severity. Lancet (2013) 3.90
Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis (2006) 3.66
The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis (2010) 3.51
Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med (2009) 3.49
Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. Am J Epidemiol (2006) 3.48
School closure and mitigation of pandemic (H1N1) 2009, Hong Kong. Emerg Infect Dis (2010) 3.42
Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis (2012) 3.35
Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness. Int J Epidemiol (2007) 3.33
Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis (2009) 3.31
Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis (2010) 3.29
Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis (2009) 3.26
Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother (2005) 3.04
Quantum walks of correlated photons. Science (2010) 3.04
Mask use, hand hygiene, and seasonal influenza-like illness among young adults: a randomized intervention trial. J Infect Dis (2010) 3.02
Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis (2013) 3.00
The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis (2004) 2.96
Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis (2008) 2.93
Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis (2012) 2.91
Influenza virus in human exhaled breath: an observational study. PLoS One (2008) 2.89
The burden of influenza-associated critical illness hospitalizations. Crit Care Med (2014) 2.84
Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses (2009) 2.82
Household responses to school closure resulting from outbreak of influenza B, North Carolina. Emerg Infect Dis (2008) 2.74
Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis (2005) 2.72
Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. Vaccine (2013) 2.69
Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med (2013) 2.65
Circulating influenza virus, climatic factors, and acute myocardial infarction: a time series study in England and Wales and Hong Kong. J Infect Dis (2011) 2.64
Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA (2010) 2.48
How to maintain surveillance for novel influenza A H1N1 when there are too many cases to count. Lancet (2009) 2.44
Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus. Clin Infect Dis (2010) 2.36
Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics (2008) 2.29
Epidemiological characteristics of 2009 (H1N1) pandemic influenza based on paired sera from a longitudinal community cohort study. PLoS Med (2011) 2.26
Influenza- and RSV-associated hospitalizations among adults. Vaccine (2006) 2.23
Monitoring influenza activity in the United States: a comparison of traditional surveillance systems with Google Flu Trends. PLoS One (2011) 2.21
Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis (2011) 2.19
Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics (2004) 2.08
Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis (2011) 2.08
Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season. J Infect Dis (2013) 2.07
Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit. Pediatrics (2003) 2.03
Influenza virus aerosols in human exhaled breath: particle size, culturability, and effect of surgical masks. PLoS Pathog (2013) 2.02
Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep (2015) 2.01
Pandemic influenza: an inconvenient mutation. Science (2009) 2.00
Nonpharmaceutical influenza mitigation strategies, US communities, 1918-1920 pandemic. Emerg Infect Dis (2006) 1.96
Transmissibility of seasonal and pandemic influenza in a cohort of households in Hong Kong in 2009. Epidemiology (2011) 1.95
Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS One (2011) 1.94
Sample size considerations for one-to-one animal transmission studies of the influenza A viruses. PLoS One (2013) 1.92
Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling. PLoS Med (2010) 1.83
Effect of interventions on influenza A (H9N2) isolation in Hong Kong's live poultry markets, 1999-2005. Emerg Infect Dis (2007) 1.82
The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine (2013) 1.79
Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis (2010) 1.76
Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol (2006) 1.74
Estimating influenza-associated deaths in the United States. Am J Public Health (2009) 1.73
Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine (2009) 1.71
Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med (2013) 1.71
Influenza-associated mortality in temperate and subtropical Chinese cities, 2003-2008. Bull World Health Organ (2012) 1.69
Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005-2011. PLoS One (2013) 1.64
Symptomatic predictors of influenza virus positivity in children during the influenza season. Clin Infect Dis (2006) 1.62
Effectiveness of interventions to reduce contact rates during a simulated influenza pandemic. Emerg Infect Dis (2007) 1.59
Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children: 2003-2004. Pediatr Infect Dis J (2006) 1.59
Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J Infect Dis (2008) 1.58
Integrated compact optical vortex beam emitters. Science (2012) 1.58
Comment on "Seroevidence for H5N1 influenza infections in humans: meta-analysis". Science (2012) 1.58
Obesity, physical activity, and mortality in a prospective chinese elderly cohort. Arch Intern Med (2006) 1.57
Excess mortality associated with influenza A and B virus in Hong Kong, 1998-2009. J Infect Dis (2012) 1.54
Clinical and nonclinical health care workers faced a similar risk of acquiring 2009 pandemic H1N1 infection. Clin Infect Dis (2011) 1.54
Factors affecting QuickVue Influenza A + B rapid test performance in the community setting. Diagn Microbiol Infect Dis (2009) 1.52
Eczematous skin disease and recall of past diagnoses: implications for smallpox vaccination. Ann Intern Med (2003) 1.48
Infection fatality risk of the pandemic A(H1N1)2009 virus in Hong Kong. Am J Epidemiol (2013) 1.47
Estimating infection attack rates and severity in real time during an influenza pandemic: analysis of serial cross-sectional serologic surveillance data. PLoS Med (2011) 1.46
Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. MMWR Morb Mortal Wkly Rep (2014) 1.44
Household transmission of 2009 pandemic influenza A (H1N1): a systematic review and meta-analysis. Epidemiology (2012) 1.43
Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic. Proc Natl Acad Sci U S A (2010) 1.42